Cellebrite DI Ltd. $CLBT Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 40.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 359,764 shares of the company’s stock after buying an additional 103,568 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Cellebrite DI were worth $6,652,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Y.D. More Investments Ltd raised its position in Cellebrite DI by 76.2% in the second quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock worth $7,065,000 after acquiring an additional 191,020 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Cellebrite DI during the 2nd quarter worth $657,000. Moody National Bank Trust Division acquired a new position in shares of Cellebrite DI during the 3rd quarter worth $2,670,000. MQS Management LLC purchased a new position in shares of Cellebrite DI in the 2nd quarter valued at about $256,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Cellebrite DI in the 2nd quarter valued at about $224,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $15.87 on Monday. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The company has a market capitalization of $3.80 billion, a PE ratio of 51.19, a price-to-earnings-growth ratio of 2.21 and a beta of 1.28. The firm’s 50-day moving average is $17.85 and its two-hundred day moving average is $16.98.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The business had revenue of $126.03 million for the quarter, compared to analysts’ expectations of $122.98 million. During the same period last year, the business earned $0.14 earnings per share. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on CLBT. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Lake Street Capital boosted their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Bank of America upped their price target on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Needham & Company LLC raised their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.